Cooperative Agreement U01FD008316
Award Date
9/1/24
Completion Date
8/31/27
Dollars Obligated
$298K
Funding Federal Agency
Center for Drug Evaluation and Research
Awarding Federal Agency
FDA Office of Acquisition and Grant Services
Federal Grant Program
93.103
Assistance Type
Cooperative Agreement
Place of Performance
ROXBURY CROSSING, MA 02120, USA
Similar Awards
This $1.5 million cooperative agreement from the Department of Health and Human Services' Food and Drug Administration (FDA) Research program (CFDA 93.103) supports the development and validation of a best practices framework for physiologically-based pharmacokinetic (PBPK) analysis to support model-informed biowaivers of fed bioequivalence studies for Biopharmaceutics Classification System Class II drugs. The University of Florida is the primary awardee. Under the award, the University of...
The U.S. Food and Drug Administration (FDA) awarded a $249,485 Cooperative Agreement under the FDA Research program (CFDA 93.103) to Simulations Plus Inc. for the project "From Bench to Bioequivalence: In Vitro Mechanistic Understanding of ASD Drug Products in Simulated Gastrointestinal Conditions." The project aims to enhance understanding of how food and gastric pH affect the release of drugs from amorphous solid dispersions (ASDs) and how formulation and manufacturing variability...
This Cooperative Agreement award from the Food and Drug Administration (FDA) under the FDA Research program (CFDA 93.103) provides $549,485 to Oklahoma State University (OSU) to develop advanced computational models integrating computational fluid dynamics, discrete element method, and machine learning to quantify variability in inhaler design, drug formulation, and user factors affecting the comparability and bioequivalence of generic orally inhaled drug products (OIDPs). The key objectives are...
This Cooperative Agreement award from the Food and Drug Administration (FDA) under the FDA Research program (CFDA 93.103) provides $499,994 to Mainehealth to study and test solutions for increasing the enrollment of non-English speaking research subjects in clinical trials. The project, titled "Increasing Clinical Trial Opportunities and Enrollment of Non-English Speaking Research Subjects: A Revised Research Pathway (INCLUDE)", aims to develop a culturally appropriate and efficient...
The Department of Health and Human Services' Food and Drug Administration (FDA) awarded a $598,728 Cooperative Agreement under the FDA Research program (CFDA 93.103) to the University of Texas at Austin to develop physiologically-based pharmacokinetic (PBPK) model-based in vitro-in vivo correlations (IVIVC) for poly(lactic-co-glycolic acid) (PLGA) implants. The project aims to (1) develop a bio-predictive in-vitro release testing method and determine how critical formulation and...
The Cooperative Agreement award U01FD008415, provided by the Food and Drug Administration (FDA) under the FDA Research program (CFDA 93.103), is supporting research to evaluate the suitability of Emulate Inc.'s Liver-Chip technology for predicting drug-induced liver injury (DILI) risk. The $250,000 award, running from September 2024 to August 2026, aims to demonstrate the reproducibility and performance of the Liver-Chip across multiple human hepatocyte donors. This research supports critical...
This Project Grant award from the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), will leverage artificial intelligence methods and electronic health records to conduct pharmacoepidemiologic studies on adverse pediatric outcomes associated with maternal substance use during pregnancy and pediatric drug exposures. The goal is to develop a stakeholder-informed real-time pediatric...
This Cooperative Agreement award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $443,527 to Brigham & Women's Hospital, Inc. to conduct translational research to advance the understanding and clinical care of antibiotic-induced delayed-type drug hypersensitivity reactions. The project aims to investigate potential "X-factors" that may critically drive the onset, phenotype,...
This $28,000,000 Cooperative Agreement awarded by the Food and Drug Administration (FDA) under the FDA Research program (CFDA 93.103) supports the National Environmental Health Association (NEHA) in a multi-year project to expand state, local, tribal, and territorial (SLTT) conformance with the Voluntary National Retail Food Regulatory Program Standards. The key objectives of this project are to: 1) Develop and improve a grant management system to provide financial assistance to SLTT retail food...
This federal Project Grant award of $500,000.00 was made on September 30, 2024 by the Agency for Healthcare Research and Quality (AHRQ) under the Research on Healthcare Costs, Quality and Outcomes (CFDA 93.226) program. The grant was awarded to Brigham & Women's Hospital Inc., a subsidiary of the larger Partners Healthcare System Incorporated, to conduct research on the relationships between diagnosis quality, clinician time and stress. The key objectives of the 4-year project are to: 1)...